Logo image of ENTX

ENTERA BIO LTD (ENTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ENTX - IL0011429839 - Common Stock

2.53 USD
-0.05 (-1.94%)
Last: 11/21/2025, 8:25:16 PM
2.53 USD
0 (0%)
After Hours: 11/21/2025, 8:25:16 PM
Fundamental Rating

3

Overall ENTX gets a fundamental rating of 3 out of 10. We evaluated ENTX against 535 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ENTX as it has an excellent financial health rating, but there are worries on the profitability. ENTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ENTX had negative earnings in the past year.
In the past year ENTX has reported a negative cash flow from operations.
In the past 5 years ENTX always reported negative net income.
In the past 5 years ENTX always reported negative operating cash flow.
ENTX Yearly Net Income VS EBIT VS OCF VS FCFENTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

ENTX's Return On Assets of -53.91% is in line compared to the rest of the industry. ENTX outperforms 46.54% of its industry peers.
With a decent Return On Equity value of -61.44%, ENTX is doing good in the industry, outperforming 60.75% of the companies in the same industry.
Industry RankSector Rank
ROA -53.91%
ROE -61.44%
ROIC N/A
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
ENTX Yearly ROA, ROE, ROICENTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ENTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTX Yearly Profit, Operating, Gross MarginsENTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

ENTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ENTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ENTX has been increased compared to 5 years ago.
ENTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ENTX Yearly Shares OutstandingENTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ENTX Yearly Total Debt VS Total AssetsENTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

ENTX has an Altman-Z score of 19.56. This indicates that ENTX is financially healthy and has little risk of bankruptcy at the moment.
ENTX's Altman-Z score of 19.56 is amongst the best of the industry. ENTX outperforms 89.53% of its industry peers.
There is no outstanding debt for ENTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.56
ROIC/WACCN/A
WACC8.79%
ENTX Yearly LT Debt VS Equity VS FCFENTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 10.47 indicates that ENTX has no problem at all paying its short term obligations.
ENTX has a Current ratio of 10.47. This is amongst the best in the industry. ENTX outperforms 83.36% of its industry peers.
ENTX has a Quick Ratio of 10.47. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 10.47, ENTX belongs to the best of the industry, outperforming 83.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.47
Quick Ratio 10.47
ENTX Yearly Current Assets VS Current LiabilitesENTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

ENTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
The Revenue has been decreasing by -5.49% on average over the past years.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-31.78%
Revenue growth 5Y-5.49%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -65.34% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-30.56%
EPS Next 2Y-65.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-69.78%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTX Yearly Revenue VS EstimatesENTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 2025 0 200K 400K
ENTX Yearly EPS VS EstimatesENTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTX Price Earnings VS Forward Price EarningsENTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTX Per share dataENTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A cheap valuation may be justified as ENTX's earnings are expected to decrease with -65.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-65.34%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ENTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENTERA BIO LTD

NASDAQ:ENTX (11/21/2025, 8:25:16 PM)

After market: 2.53 0 (0%)

2.53

-0.05 (-1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-26 2026-03-26/amc
Inst Owners22.05%
Inst Owner Change-10.05%
Ins Owners2.42%
Ins Owner Change2.77%
Market Cap115.52M
Revenue(TTM)181.00K
Net Income(TTM)-10.60M
Analysts82.86
Price Target10.2 (303.16%)
Short Float %0.57%
Short Ratio1.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)115.28%
Min EPS beat(2)46.52%
Max EPS beat(2)184.03%
EPS beat(4)3
Avg EPS beat(4)50.04%
Min EPS beat(4)-56.86%
Max EPS beat(4)184.03%
EPS beat(8)7
Avg EPS beat(8)30.94%
EPS beat(12)10
Avg EPS beat(12)25.41%
EPS beat(16)14
Avg EPS beat(16)25.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)43.75%
EPS NY rev (1m)0%
EPS NY rev (3m)41.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 695.9
P/FCF N/A
P/OCF N/A
P/B 6.69
P/tB 6.69
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.38
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.91%
ROE -61.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 108.11%
Cap/Sales 24.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.47
Quick Ratio 10.47
Altman-Z 19.56
F-Score5
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)40.07%
Cap/Depr(5y)48.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y-30.56%
EPS Next 2Y-65.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-31.78%
Revenue growth 5Y-5.49%
Sales Q2Q%N/A
Revenue Next Year-69.78%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.32%
OCF growth 3YN/A
OCF growth 5YN/A

ENTERA BIO LTD / ENTX FAQ

What is the fundamental rating for ENTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to ENTX.


What is the valuation status for ENTX stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTERA BIO LTD (ENTX). This can be considered as Overvalued.


How profitable is ENTERA BIO LTD (ENTX) stock?

ENTERA BIO LTD (ENTX) has a profitability rating of 1 / 10.